Home Neglected Parasitic Diseases Drug Development Consortium News Contact Photeomix PI, Iain Pemberton Created in 2005 in the Paris biocluster, France.  Photeomix founded Activomics®, activity-based proteomics research services in biomarker and drug discovery.   Coupled with fragment based drug design, Activomics® is charting the differential drugability of the proteome as a key point in development of new anti-kinetoplastid drugs in the KINDReD consortium.         NovAlix PI, Denis Zeyer NovAliX is a French SME NovAliX that was established in 2003 with the goal of providing industry researchers with knowledge and enabling capabilities in chemistry and biophysics. Built on its world class academic legacy from Strasbourg University and IGBMC in the field of organic chemistry and structural biology, NovAliX has assembled a team of 120 highly talented scientists complemented by an outstanding platform in biophysics to support the pharmaceutical industry's outsourcing needs from discovery to manufacturing.            Graffinity PI, Thomas Neuman Founded in 1997 in the heart of the biotech cluster in Heidelberg, Germany. Graffinity’s unique SPR microarray platform will play a pivitol role in the fragment based screening and drug design objectives of the programme. With their fragment based drug discovery platform they provide their partners with novel small molecules for drug discovery and chemical genomics approaches.          Innoprot PI, Isbaal Ramos Founded in Spain..        Phylogene PI, Gilbert Skorski Founded in 1e programme.
© IP Research Consulting 2014

Biotechnology Partners

Website Website Technologies Technologies Technologies Technologies Technologies Technologies Technologies Technologies Website Website Technologies Technologies Website Website Website Website